Get started
Author

Viçent Serra

Observed name: V. Serra
OpenAlex ID: A5018259701
Impact of Morbid Obesity and Obesity Phenotype on Outcomes After Transcatheter Aortic Valve Replacement
2021 · Angela McInerney, Gabriela Tirado‐Conte, et al. · Journal of the American Heart Association · 32
Transcatheter aortic valve replacement in obese patients: procedural vascular complications with the trans-femoral and trans-carotid access routes
2021 · Alberto Alperi, Angela McInerney, et al. · Interactive Cardiovascular and Thoracic Surgery · 18
PDF
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
2021 · A. Llop-Guevara, V. Vladimirova, et al. · Annals of Oncology · 5
Abstract RF5-05: Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial
2026 · I. Pimentel, T. Pascual, et al. · Clinical Cancer Research · 2
266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
2024 · G. Villacampa, N. Filmann, et al. · Annals of Oncology · 1
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer
2026 · M. Cruellas, A. Rodriguez-Hernandez, et al. · ESMO Open
PDF
Omomyc as a novel therapeutic strategy against metastatic triplenegative breast cancer, alone and in combination with the standard of care
2022 · F. Giuntini, D. Massó-Vallés, et al. · European Journal of Cancer
Works count: 7
Citation count: 58
H-index: 3
I10-index: 2
Year
Topic
Type